Structure Therapeutics
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on leveraging structure-based drug design to develop more accessible oral small molecule therapeutics for chronic diseases such as obesity. With expertise in GPCR biology, the company aims to make medicines broadly accessible, overcoming limitations of biologics and peptides, and addressing the global obesity pandemic. Their pipeline includes innovative treatments targeting metabolic and cardiopulmonary conditions, emphasizing scalability, stability, and cost-effectiveness to meet growing healthcare demands.
Industries
Nr. of Employees
medium (51-250)
Patents
Compounds and compositions for treating conditions associated with APJ receptor activity
US-11944622-B2
View DetailsCompounds and compositions for treating conditions associated with APJ receptor activity
US-11471455-B2
View Details
Compounds and compositions for treating conditions associated with APJ receptor activity
US-11944622-B2
View DetailsCompounds and compositions for treating conditions associated with APJ receptor activity
US-11471455-B2
View DetailsProducts
Oral small-molecule GLP‑1 receptor agonist (clinical candidate)
An orally available small-molecule GLP‑1 receptor agonist advanced into first-in-human single-ascending-dose studies with reported early clinical safety and pharmacology data.
Oral dual amylin/calcitonin receptor agonist (preclinical/clinical candidate)
An oral small molecule designed to agonize amylin and calcitonin receptors for obesity therapy, supported by preclinical data and conference presentations.
G-protein biased apelin receptor agonist (pulmonary disease candidate)
A small-molecule apelin receptor agonist optimized for G-protein biased signaling, with reported preclinical discovery and early clinical single/multiple ascending dose studies.
Oral small-molecule GLP‑1 receptor agonist (clinical candidate)
An orally available small-molecule GLP‑1 receptor agonist advanced into first-in-human single-ascending-dose studies with reported early clinical safety and pharmacology data.
Oral dual amylin/calcitonin receptor agonist (preclinical/clinical candidate)
An oral small molecule designed to agonize amylin and calcitonin receptors for obesity therapy, supported by preclinical data and conference presentations.
G-protein biased apelin receptor agonist (pulmonary disease candidate)
A small-molecule apelin receptor agonist optimized for G-protein biased signaling, with reported preclinical discovery and early clinical single/multiple ascending dose studies.
Expertise Areas
- Structure-based drug discovery
- GPCR structural biology and targeting
- Computational chemistry and physics-based molecular modeling
- Data science and analytics for drug discovery
Key Technologies
- X-ray crystallography (including serial femtosecond/XFEL)
- High-throughput protein crystallization (LCP, nanodroplet, restricted geometry)
- Cryo-electron microscopy and tomography
- NMR spectroscopy for membrane proteins
News & Updates
On August 6, 2025, the company announced its financial results and recent highlights.
On June 20, 2025, the company announced poster presentations at ADA 2025, including preclinical data for ACCG-2671.
On May 29, 2025, the company announced participation in upcoming investor conferences.
Structure Therapeutics has contributed to numerous scientific publications, advancing membrane protein research, crystallization techniques, and structural biology, including high-resolution structures of GPCRs and innovative assay methods.
On August 6, 2025, the company announced its financial results and recent highlights.
On June 20, 2025, the company announced poster presentations at ADA 2025, including preclinical data for ACCG-2671.
On May 29, 2025, the company announced participation in upcoming investor conferences.
Structure Therapeutics has contributed to numerous scientific publications, advancing membrane protein research, crystallization techniques, and structural biology, including high-resolution structures of GPCRs and innovative assay methods.